These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29411361)

  • 1. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo.
    Hasanovic A; Ruggiero C; Jung S; Rapa I; Signetti L; Ben Hadj M; Terzolo M; Beuschlein F; Volante M; Hantel C; Lalli E; Mus-Veteau I
    Int J Cancer; 2018 Jul; 143(1):199-211. PubMed ID: 29411361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells.
    Durand N; Simsir M; Signetti L; Labbal F; Ballotti R; Mus-Veteau I
    Molecules; 2021 Mar; 26(7):. PubMed ID: 33810240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity.
    Hasanovic A; Simsir M; Choveau FS; Lalli E; Mus-Veteau I
    Biomedicines; 2020 Jul; 8(8):. PubMed ID: 32751066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Multidrug Transporter Ptch1 Potentiates Chemotherapy Efficiency.
    Hasanovic A; Mus-Veteau I
    Cells; 2018 Aug; 7(8):. PubMed ID: 30110910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
    Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma.
    Beuschlein F; Jakoby J; Mentz S; Zambetti G; Jung S; Reincke M; Süss R; Hantel C
    Mol Cell Endocrinol; 2016 Jun; 428():82-8. PubMed ID: 26994514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural paniceins from mediterranean sponge inhibit the multidrug resistance activity of Patched and increase chemotherapy efficiency on melanoma cells.
    Fiorini L; Tribalat MA; Sauvard L; Cazareth J; Lalli E; Broutin I; Thomas OP; Mus-Veteau I
    Oncotarget; 2015 Sep; 6(26):22282-97. PubMed ID: 26068979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
    Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
    Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen.
    Wang L; Lyu Y; Li Y; Li K; Wen H; Feng C; Li N
    Aging (Albany NY); 2021 Sep; 13(18):22286-22297. PubMed ID: 34536950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
    Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
    Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
    Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
    Jung S; Nagy Z; Fassnacht M; Zambetti G; Weiss M; Reincke M; Igaz P; Beuschlein F; Hantel C
    Endocr Relat Cancer; 2016 Oct; 23(10):825-37. PubMed ID: 27550961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
    Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
    Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.
    Creemers SG; van Koetsveld PM; De Herder WW; Dogan F; Franssen GJH; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Mar; 26(3):367-378. PubMed ID: 30650062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.